These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 22518836)
1. Mitochondrial dysfunction in skeletal muscle of amyloid precursor protein-overexpressing mice. Boncompagni S; Moussa CE; Levy E; Pezone MJ; Lopez JR; Protasi F; Shtifman A J Biol Chem; 2012 Jun; 287(24):20534-44. PubMed ID: 22518836 [TBL] [Abstract][Full Text] [Related]
2. Intracellular β-amyloid accumulation leads to age-dependent progression of Ca2+ dysregulation in skeletal muscle. Lopez JR; Shtifman A Muscle Nerve; 2010 Nov; 42(5):731-8. PubMed ID: 20665519 [TBL] [Abstract][Full Text] [Related]
3. Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Sugarman MC; Kitazawa M; Baker M; Caiozzo VJ; Querfurth HW; LaFerla FM Neurobiol Aging; 2006 Mar; 27(3):423-32. PubMed ID: 15950323 [TBL] [Abstract][Full Text] [Related]
4. Primary over-expression of AβPP in muscle does not lead to the development of inclusion body myositis in a new lineage of the MCK-AβPP transgenic mouse. Luo YB; Johnsen RD; Griffiths L; Needham M; Fabian VA; Fletcher S; Wilton SD; Mastaglia FL Int J Exp Pathol; 2013 Dec; 94(6):418-25. PubMed ID: 24205796 [TBL] [Abstract][Full Text] [Related]
5. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Sugarman MC; Yamasaki TR; Oddo S; Echegoyen JC; Murphy MP; Golde TE; Jannatipour M; Leissring MA; LaFerla FM Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6334-9. PubMed ID: 11972038 [TBL] [Abstract][Full Text] [Related]
7. Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. Moussa CE; Fu Q; Kumar P; Shtifman A; Lopez JR; Allen PD; LaFerla F; Weinberg D; Magrane J; Aprahamian T; Walsh K; Rosen KM; Querfurth HW FASEB J; 2006 Oct; 20(12):2165-7. PubMed ID: 16940437 [TBL] [Abstract][Full Text] [Related]
8. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. Askanas V; Engel WK; Nogalska A J Neuropathol Exp Neurol; 2012 Aug; 71(8):680-93. PubMed ID: 22805774 [TBL] [Abstract][Full Text] [Related]
9. Genetically increasing flux through β-oxidation in skeletal muscle increases mitochondrial reductive stress and glucose intolerance. Smith CD; Lin CT; McMillin SL; Weyrauch LA; Schmidt CA; Smith CA; Kurland IJ; Witczak CA; Neufer PD Am J Physiol Endocrinol Metab; 2021 May; 320(5):E938-E950. PubMed ID: 33813880 [TBL] [Abstract][Full Text] [Related]
10. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Kitazawa M; Green KN; Caccamo A; LaFerla FM Am J Pathol; 2006 Jun; 168(6):1986-97. PubMed ID: 16723713 [TBL] [Abstract][Full Text] [Related]
11. Cultured inclusion-body myositis muscle fibers do not accumulate beta-amyloid precursor protein and can be innervated. McFerrin J; Engel WK; Askanas V Neurology; 1999 Dec; 53(9):2184-7. PubMed ID: 10599804 [TBL] [Abstract][Full Text] [Related]
12. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Vattemi G; Nogalska A; King Engel W; D'Agostino C; Checler F; Askanas V Acta Neuropathol; 2009 May; 117(5):569-74. PubMed ID: 19280202 [TBL] [Abstract][Full Text] [Related]
13. Transgenic mice expressing the human C99 terminal fragment of betaAPP: effects on cytochrome oxidase activity in skeletal muscle and brain. Strazielle C; Dumont M; Fukuchi K; Lalonde R J Chem Neuroanat; 2004 Jul; 27(4):237-46. PubMed ID: 15261330 [TBL] [Abstract][Full Text] [Related]
14. Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice. Askanas V; Engel WK Am J Pathol; 1998 Dec; 153(6):1673-7. PubMed ID: 9846956 [No Abstract] [Full Text] [Related]
15. Beta-amyloid peptide expression is sufficient for myotube death: implications for human inclusion body myopathy. Querfurth HW; Suhara T; Rosen KM; McPhie DL; Fujio Y; Tejada G; Neve RL; Adelman LS; Walsh K Mol Cell Neurosci; 2001 May; 17(5):793-810. PubMed ID: 11358479 [TBL] [Abstract][Full Text] [Related]
16. Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Fukuchi K; Pham D; Hart M; Li L; Lindsey JR Am J Pathol; 1998 Dec; 153(6):1687-93. PubMed ID: 9846958 [TBL] [Abstract][Full Text] [Related]
17. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Jin LW; Hearn MG; Ogburn CE; Dang N; Nochlin D; Ladiges WC; Martin GM Am J Pathol; 1998 Dec; 153(6):1679-86. PubMed ID: 9846957 [TBL] [Abstract][Full Text] [Related]
18. Downregulation and increased turnover of beta-amyloid precursor protein in skeletal muscle cultures by neuregulin-1. Rosen KM; Ford BD; Querfurth HW Exp Neurol; 2003 Jun; 181(2):170-80. PubMed ID: 12781990 [TBL] [Abstract][Full Text] [Related]